Alexander Foster, MD
Cornea and External Diseases Specialist · Encinitas, CANPI 1033407275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,360 of the $28,874 with a category attached, or 80.9%. Rxsight Inc accounts for 61.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $15,771 and has fallen 82.0% since, to $2,838 in 2025.
Across 151 payments — averaging $191.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$18K
- Johnson & Johnson Surgical Vision, Inc.$6K
- Alcon$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$496
- Bausch & Lomb Americas Inc.$453
- AbbVie$334
- plus $2K from 19 others
What the payments were for
- Consulting fees$23,36081%
- Speaking & faculty fees$260%
- Travel & lodging$150%
- Food & beverage$5,41619%
- Entertainment$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 9 | $17,724 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $6,412 |
| Alcon | 31 | $1,835 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $496 |
| Bausch & Lomb Americas Inc. | 19 | $453 |
| AbbVie(2 entities) | 10 | $334 |
| Glaukos Corporation | 3 | $226 |
| Harrow Eye, LLC | 7 | $209 |
| NEW World Medical,inc. | 1 | $166 |
| Novartis | 8 | $165 |
| Aerie Pharmaceuticals, Inc. | 3 | $142 |
| Kala Pharmaceuticals, Inc. | 6 | $121 |
| Oyster Point Pharma, Inc. | 4 | $101 |
| Astellas Pharma US Inc | 4 | $95 |
| Dompe US, Inc. | 4 | $92 |
| Optos, Inc. | 3 | $57 |
| Thea Pharma Inc. | 3 | $54 |
| Biotissue Holdings Inc. | 2 | $45 |
| Amgen(2 entities) | 2 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Beaver-visitec International, Inc. | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Ivantis, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$15,350
- Tecnis Simplicity$6,020
- Tecnis IOL$6,008
- LIGHT ADJUSTABLE LENS (LAL)$2,250
- RXSIGHT CONTACT LENS$2,250
- RXSIGHT INJECTOR HANDPIECE$2,250
- RXSIGHT INJECTOR CARTRIDGE$2,250
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,250
- AcrySof$502
- ORA$375
- ACTIVEFOCUS$364
- enVista MX60 IOL$288
- LenSx$259
- Centurion$253
- ReSTOR$238
- Clareon$221
- iDoseTR$188
- Ahmed Glaucoma Valve$166
- Kahook Dual Blade$166
- AcrySof IQ PanOptix$137
How this compares
$28,874 in reported general payments places this provider in the 80th percentile of 50 cornea and external diseases specialist providers in California.
See all cornea and external diseases specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $24,555 |
| XiidraLifitegrast | 17 | $16,505 |
| LumiganBimatoprost | 26 | $15,524 |
| Prednisolone Acetate | 336 | $9,575 |
| Cyclosporine | 37 | $9,343 |
| Bromfenac Sodium | 23 | $2,922 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $2,260 |
| Travoprost | 17 | $1,703 |
| Loteprednol Etabonate | 11 | $1,362 |
| Timolol Maleate | 62 | $1,221 |
| Latanoprost | 135 | $1,188 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,075 |
| ValacyclovirValacyclovir Hcl | 18 | $983 |
| MoxifloxacinMoxifloxacin Hcl | 36 | $896 |
| Doxycycline Hyclate | 35 | $855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $334 | $40,07856 claims |
| Bausch & Lomb Americas Inc.Xiidra | $453 | $16,50517 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $496 | $1,36211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 cornea and external diseases specialist providers in California.
Other cornea and external diseases specialist in Encinitas
- Sumit GargIrvine$808K
- Jillian ChongBeverly Hills$113K
- Tyson KimSan Francisco$91K
- Edward MancheStanford$78K
- Michael SavetskyCulver City$63K
- Michael SaidelSonoma$51K
- Matthew WadeIrvine$38K
- Lawrence ChaoIrvine$36K
- William ChristianSanta Monica$33K
- Jimmy LeeIrvine$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.